Literature DB >> 10482591

Role of dendritic cells in the immune response induced by mouse mammary tumor virus superantigen.

F Baribaud1, I Maillard, S Vacheron, T Brocker, H Diggelmann, H Acha-Orbea.   

Abstract

After mouse mammary tumor virus (MMTV) infection, B lymphocytes present a superantigen (Sag) and receive help from the unlimited number of CD4(+) T cells expressing Sag-specific T-cell receptor Vbeta elements. The infected B cells divide and differentiate, similarly to what occurs in classical B-cell responses. The amplification of Sag-reactive T cells can be considered a primary immune response. Since B cells are usually not efficient in the activation of naive T cells, we addressed the question of whether professional antigen-presenting cells such as dendritic cells (DCs) are responsible for T-cell priming. We show here, using MMTV(SIM), a viral isolate which requires major histocompatibility complex class II I-E expression to induce a strong Sag response in vivo, that transgenic mice expressing I-E exclusively on DCs (I-EalphaDC tg) reveal a strong Sag response. This Sag response was dependent on the presence of B cells, as indicated by the absence of stimulation in I-EalphaDC tg mice lacking B cells (I-EalphaDC tg muMT(-/-)), even if these B cells lack I-E expression. Furthermore, the involvement of either residual transgene expression by B cells or transfer of I-E from DCs to B cells was excluded by the use of mixed bone marrow chimeras. Our results indicate that after priming by DCs in the context of I-E, the MMTV(SIM) Sag can be recognized on the surface of B cells in the context of I-A. The most likely physiological relevance of the lowering of the antigen threshold required for T-cell/B-cell collaboration after DC priming is to allow B cells with a low affinity for antigen to receive T-cell help in a primary immune response.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482591      PMCID: PMC112858          DOI: 10.1128/JVI.73.10.8403-8410.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Infection of terminally differentiated myotubes with Rous sarcoma virus (RSV): lack of DNA integration but presence of RSV mRNA.

Authors:  A Tanaka; H Hara; H T Park; J Wolfert; M Fujihara; R Izutani; A Kaji
Journal:  J Gen Virol       Date:  1992-07       Impact factor: 3.891

Review 2.  Antigen presentation by B lymphocytes to CD4+ T lymphocytes in vivo: importance for B lymphocyte and T lymphocyte activation.

Authors:  F D Finkelman; A Lees; S C Morris
Journal:  Semin Immunol       Date:  1992-08       Impact factor: 11.130

Review 3.  Antigen uptake and presentation by dendritic leukocytes.

Authors:  J M Austyn
Journal:  Semin Immunol       Date:  1992-08       Impact factor: 11.130

4.  B cells turn off virgin but not memory T cells.

Authors:  E J Fuchs; P Matzinger
Journal:  Science       Date:  1992-11-13       Impact factor: 47.728

5.  Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells.

Authors:  P U Cameron; P S Freudenthal; J M Barker; S Gezelter; K Inaba; R M Steinman
Journal:  Science       Date:  1992-07-17       Impact factor: 47.728

6.  Infection of terminally differentiated myotubes with Rous sarcoma virus: reduced synthesis of env and v-src proteins.

Authors:  K J Hsia; H Hara; R Izutani; H T Park; M Fujihara; A Kaji
Journal:  J Gen Virol       Date:  1992-07       Impact factor: 3.891

7.  Clonal deletion of self-reactive T cells in irradiation bone marrow chimeras and neonatally tolerant mice. Evidence for intercellular transfer of Mlsa.

Authors:  D E Speiser; R Schneider; H Hengartner; H R MacDonald; R M Zinkernagel
Journal:  J Exp Med       Date:  1989-08-01       Impact factor: 14.307

8.  Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus.

Authors:  W Held; A N Shakhov; S Izui; G A Waanders; L Scarpellino; H R MacDonald; H Acha-Orbea
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

9.  An exogenous mouse mammary tumor virus with properties of Mls-1a (Mtv-7).

Authors:  W Held; A N Shakhov; G Waanders; L Scarpellino; R Luethy; J P Kraehenbuhl; H R MacDonald; H Acha-Orbea
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

10.  Phagocytosis of antigens by Langerhans cells in vitro.

Authors:  C Reis e Sousa; P D Stahl; J M Austyn
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

View more
  6 in total

1.  Critical role of dendritic cells in mouse mammary tumor virus in vivo infection.

Authors:  Maria Cecilia Courreges; Dalia Burzyn; Irene Nepomnaschy; Isabel Piazzon; Susan R Ross
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

Review 2.  Mouse Mammary Tumor Virus (MMTV) and MMTV-like Viruses: An In-depth Look at a Controversial Issue.

Authors:  Francesca Parisi; Giulia Freer; Chiara Maria Mazzanti; Mauro Pistello; Alessandro Poli
Journal:  Viruses       Date:  2022-05-06       Impact factor: 5.818

3.  Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life cycle.

Authors:  M Mpandi; L A Otten; C Lavanchy; H Acha-Orbea; D Finke
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

4.  Toll-like receptor 4-dependent activation of dendritic cells by a retrovirus.

Authors:  Dalia Burzyn; John C Rassa; David Kim; Irene Nepomnaschy; Susan R Ross; Isabel Piazzon
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

5.  Endogenous MMTV proviruses induce susceptibility to both viral and bacterial pathogens.

Authors:  Sanchita Bhadra; Mary M Lozano; Shelley M Payne; Jaquelin P Dudley
Journal:  PLoS Pathog       Date:  2006-12       Impact factor: 6.823

Review 6.  Intestinal Immune System and Amplification of Mouse Mammary Tumor Virus.

Authors:  Lankai Chen; Xipeng Zhang; Guisheng Liu; Shuo Chen; Minying Zheng; Siwei Zhu; Shiwu Zhang
Journal:  Front Cell Infect Microbiol       Date:  2022-01-13       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.